Real-World Analysis of the Therapeutic Management and Disease Burden in Chronic Myeloid Leukemia Patients with Later Lines in Italy.

Among patients with ≥3rd line ( Figure 1 B), aside from ponatinib prescription (increased from 15% in 2015 to 20% in 2018) and imatinib (no substantial changes over the years), nilotinib, dasatinib and bosutinib did not show a clear trend.

also in 19,460 other papers

An increasing trend in the number of patients treated in ≥3rd L cohort over the year was observed, with a 97.6% increment over the index date (2015–2018) (from 41 patients in 2015 to 81 in 2018, Table 2 ).

also in 63,971 other papers